Palabras clave
toxoplasmosis
CCR5
resistencia
antirretrovirales
Latinoamérica
México
VIH
toxoplasmosis
CCR5
resistance
antiretroviral
Latin America
Mexico
Cómo citar
Resumen
El objetivo de este trabajo es determinar los factores que pueden estar asociados a la mortalidad de pacientes con SIDA en un estudio meta-analítico del 2010-2014 en el cual se revisó la literatura existente sobre SIDA y las causas de mortalidad en la base de datos del NCBI. Los datos, integrados en una matriz, fueron procesados estadísticamente siguiendo los estándares del meta-análisis en el programa Open-Epi versión 3.03. Los resultados muestran que las enfermedades secundarias, tales como tuberculosis (tasa: 0.1), toxoplasmosis (tasa: 1) y Síndrome de Kaposi (tasa: 1) siguen ocupando un lugar importante entre los factores de mortalidad de la población con SIDA a nivel global. No obstante, los datos muestran también que el mayor problema que presenta la población con SIDA es la creciente resistencia a los antirretrovirales (tasa: 10). Los polimorfismos de los receptores que intervienen en la respuesta inmunológica en la mortalidad de las poblaciones con SIDA (tasa: 0.01) tienen un bajo impacto. En México, la tasa de mortalidad de esta población es alta (tasa: 4.5) y muy similar a otros países de Latinoamérica (tasa: 3.5). Entre los determinantes de estas tasas de mortalidad en la población mexicana con SIDA podrían estar la baja restauración inmunológica y la mala respuesta a los antirretrovirales.Citas
Las referencias marcadas con un asterisco indican estudios comprendidos en el meta-análisis.
*Avilés-Salas, A., Cornejo-Juárez, P., y Sobrevilla-Calvo, P. de J. (2011). Coexistencia de linfoma plasmablástico, sarcoma Kaposi y enfermedad de Castleman en un paciente con infección por el virus de inmunodeficiencia humana. Rev Chil Infect, 28, 76-80. doi: 10.4067/S0716-10182011000100015
*Basavaprabhu, A., Soundarya, M., Deepak, M., y Satish, R. (2012). CNS Toxoplasmosis Presenting with Obstructive Hydrocephalus in Patients of Retroviral Disease-A Case Series. Med J Malaysia, 67, 214-216.
*Carganico, A., Dupke, S., Ehret, R., Berg, T., Baumgarten, A., Obermeier, M., y Walter, H. (2014). New dolutegravir resistance pattern identified in a patient failing therapy. Journal of the International AIDS Society, 17(Suppl 3). doi:10.7448/IAS.17.4.19749
*Castilho, J. L., Luz, P. M., Shepherd, B. E., Turner, M., Ribeiro, S. R., y Bebawy, S. S. (2015). HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts. Infectious Agents and Cancer, 10, 1-10.
Chatterjee, A., Rathore, A., Viddyant, S., Kakkar, K., y Dhole, T.N. (2012). Chemokines and chemokines receptors in susceptibility to HIV-1 infection and progression to AIDS. Disease Markers, 32, 143-151.
*Corrêa, V. V., Martínez, B. M. F., Mendoza-Sassi, R. A., Silveira, J. M., Soares, M. A., y Barral De Martínez, A. M. (2011). The effect of combined polymorphisms in chemokines and chemokine receptors on the clinical course of HIV-1 infection in a Brazilian population. Mem Inst Oswaldo Cruz, Rio de Janeiro, 106, 408-414.
*Cortes, C. P., Wehbe, F. H., McGowan, C. C., Shepherd, B. E., Duda, S. N., Jenkins, C. A., … Sterling, T. R. (2013). Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis. Plos One, 8. doi:10.1371/journal.pone.0074057
Dean, A.G., Sullivan, K.M., y Soe, M.M. (2015). OpenEpi: Open Source Epidemiologic Statistics for Public Health [Software]. Recuperado de www.OpenEpi.com
*Del Amo, J., Jarrin, I., May, M., Dabis, F., Crane, H., Podzamczer, D., … Gill, M. J. (2013). Influence of geographical origin and ethnicity on mortality in patients on therapy in Canada, Europe, and the United States. Clin Infect Dis, 56, 1810-1811.
Dennis, A. M., Napravnik, S., Seña, A. C., y Eron, J. J. (2011). Late Entry to HIV care among Latinos compared with no-Latinos in a Southeastern US cohort. CID, 53, 480-487.
*Fernandes, L. S. (2012). Human immunodeficiency virus and cancer. A population of HIV-infected patients at Hospital de Santa Maria and predictors of cancer. GERMS, 2(2), 60-75.
*Gheuens, S., Cheeseman, S. H., y Koralnik, I. J. (2011). Hidden in plain view: emergence of Progressive Multifocal Leukoencephalopathy after treatment of CNS Toxoplasmosis. Acta Neurol Belg, 111, 217–219.
*González, M. A., Martin, L., Muñoz, S., y Jacobson, J. O. (2011). Patterns, trends and sex differences in HIV/AIDS reported mortality in Latin American countries: 1996-2007. BMC Public Health, 11, 605. doi: 10.1186/1471-2458-11-605.
*Gopal, S., Achenbach, C. J., Yanik, E. L., Dittmer, D. P., Eron, J. J., y Engels, E.A. (2014). Moving Forward in HIV-Associated Cancer. J Clin Oncology, 32, 876-880.
*Herman, S. M., van Leth, F., Kiragga, A. N., Hoepelman, A. I. M., Lange, J. M. A., y Manabe, Y. C. (2012). Unrecognized tuberculosis at therapy initiation is associated with lower CD4+ T cell recovery. Trop Med Int Health, 17, 1527-1533.
*Hirai, Y., Yoshihara, T., Motoji, T., y Totsuka, K. (2012). Facial-oropharyngeal Kaposi Sarcoma in a HIV-seropositive man. Intern Med, 51, 2989-2990. doi:10.2169/internalmedicine.51.8620
Instituto Nacional de Estadística y Geografía de México. (2011). Tasa de Mortalidad por VIH/SIDA por 100 mil habitantes del 2009-2011. Recuperado de http://www3.inegi.org.mx/sistemas/biinegi/?ind=6300000058
Kamat, A., Misra, V., Cassol, E., Ancuta, P., Yan, Z., Li, C., Morgello, S., y Gabuzda, D. (2012). A plasma biomarker signature of immune activation in HIV patients on therapy. Plos One, 7. doi:10.1371/journal.pone.0030881
*Khabour, O. F., Abu-Haweleh, L. J., y Alzoubi, K. H. (2013). Distribution Of CCR-5D32, CCR2-64I, and SDF-1-3: A Alleles Among Jordanians. AIDS Research And Human Retroviruses, 29, 151-155.
*Kouri, V., Alemán, Y., Peréz, L., Peréz, J., Fonseca, C., Correa, C., … Laethem, K. (2014). High frequency of antiviral drug resistance and non-b subtypes in HIV-1 patients failing antiviral therapy in Cuba. Journal of the International AIDS Society, 17(Suppl 3). doi:10.7448/IAS.17.4.19754
*Kouri, V., Martínez, P. A., Capò, V., Blanco, O., Rodríguez, M. E., Jiménez, N., … Hengge, U. (2012). Kaposi’s Sarcoma and Human Herpesvirus8 in Cuba: Evidence of subtype B expansion. Virology, 432, 361–369.
*Lejeune, M. A., Mirô, J. M., Lazzari, E. D., García, F., Claramonte, X., Martínez, E., … Gallart, T. (2011). Restoration of T Cell Responses to Toxoplasma gondii after Successful Combined Therapy in Patients with AIDS with Previous Toxoplasmic Encephalitis. CID, 52, 662-670.
Liovat, A. S., Rey-Cuillè, M. A., Lecuroux, C., Jacquelin, B., Girault, I., Petitjean, G., … Müller-Trutwin, M. (2012). Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV infection. Plos One, 7. doi:10.1371/journal.pone.0046143
*Liu, W. C., Chang, L. H., Wu, P. Y., Luo, Y. Z., Wu, C. H., Su, Y. C., … Hung, C. C. (2014). Seroincidence of HIV and prevalence of transmitted drug resistance of HIV-1 strains among persons seeking voluntary counselling and testing in Taiwan. Journal of the International AIDS Society, 17(Suppl 3).
*Luu, H. N., Amirian, E. S., Chiao, E. Y., y Scheurer, M. E. (2014). Age patterns of Kaposi’s sarcoma incidence in a cohort of HIV-infected men. Cancer Med, 3, 1635–1643.
*Machala, L., Maly, M., Beran, O., Jilich, D., y Kodym, P. (2013). Incidence and clinical and immunological characteristics of primary Toxoplasma gondii infection in HIV-infected patients. Int J Infect Diseases, 17, e892–e896. doi:10.1016/j.ijid.2013.03.017
Mahajan, S., Agosto-Mojica, A., Aakinkeel, R., Raynolds, J.L., Nair, B.B., Sykes, D.E., … Schwartz, S.A. (2010). Role of chemokines and cytokine polymorphisms in the progression of HIV-1 disease. Biochem Biophys Res Commun, 396, 348-352.
*Marcelin, A.G., Charpentier, C., Wirden, M., Descamps, D., y Calvez, V. (2014). Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment. Journal of the International AIDS Society, 17(Suppl 3). doi:10.7448/IAS.17.4.19744
*McFaul, K., Lim, C., Jones, R., Asboe, D., Pozniak, A., Sonecha, S., Boffito, M., y Nwokolo, N. (2014). Transmitted drug resistance in treatment naive HIV-infected persons in London in 2011 to 2013. Journal of the International AIDS Society, 17(Suppl 3). doi:10.7448/IAS.17.4.19747.
MedCalc Software. (2015). MedCalc [Software]. Recuperado de https://www.medcalc.org/download.php
Mederos, C. L. M., Reyes, P. A., Valdés, A. L., Rodríguez, D. F., Sardiñas, A. M., Martínez, M. R., y Díaz Romero, R. (2014). Confección por Mycobacterium malmoense y Mycobacterium tuberculosis en paciente con el síndrome de inmunodeficiencia humana. Rev Perú Med Exp Salud Pública, 31, 788-792.
Mosier, D. E. (2009). How HIV changes it`s tropism: evolution and adaptation?. Curr Opin HIV AIDS, 4, 125-130.
*Nelson, B., Borok, M. Z., Mhlanga, T. O., Makadzange, A.T., y Campbell, T. B. (2013). AIDS-associated Kaposi sarcoma: outcomes after initiation of therapy at a university-affiliated hospital in urban Zimbabwe. Int J Infect Diseases, 17, e902–e906. doi:10.1016/j.ijid.2013.04.011
Nissapartorn, V., Lee, C., Fatt, K., Loon, L.C., Mahmud, R., y Abdullah, A. (2014). Toxoplasmosis in HIV/AIDS patients: A current situation. Jnp J. Infect Dis, 57, 160-165.
*Ogoina, D., Adekunle, V., Obiako, R., Umar, A., Akolawole, M., y Ovosi, J. (2011). Disseminated infections due to Immune Reconstitution Inflammatory Syndrome after Highly Active Therapy - Report of 3 cases from Nigeria. Pan African Med J, 9, 1-5.
*Osunkalu, V. O., Akanmu, S. A., Ofomah, N. J., Onyiaorah, I. V., Adediran, A., y Akinde, R.O. (2011). Seroprevalence of Toxoplasma gondii IgG antibody in HIV-infected patients at the Lagos University Teaching Hospital. HIV/AIDS - Research and Palliative Care, 3, 101–105.
*Parczewski, M., Witak-Jedra, M., Maciejewska, K., Bociaga-Jasik, M., Skwara, P., Garlicki, A., … Leszczyszyn-Pynka M. (2014).Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland. Journal of the International AIDS Society, 17(Suppl 3). doi:10.7448/IAS.17.4.19753
Pimpin, L. N., Drumright, M. E., Kruijshaar. I., Abubakar, B., Rice, V., Delpech, V., … Ködmön, C. (2011). Tuberculosis and HIV co-infection in European Union and European Economic Area countries. Eur Respir J, 38, 1382–1392.
*Pittore, B., Loris-Pelagatti, C., Deiana, F., Ortu, F., Maricosu, E., Cossu, S., y Sotgiu, G. (2015). Isolated Kaposi Sarcoma of the Tonsil: A Case Report and Review of the Scientific Literature. Case Reports in Otolaryngology, 2015. doi:10.1155/2015/874548
*Rocha-Pereira, N., Duro, R., Piñero, C., Figueiredo, C., Sofia-Santos, A., Soares, J., Serrão, R., y Sarmento, A. (2014). Primary drug resistance at diagnosis of HIV-1 infection: a Portuguese cohort. Journal of the International AIDS Society, 17(Suppl 3). doi:10.7448/IAS.17.4.19761
Rodríguez, C., Martínez, E., Bolívar, G., Sánchez, S., y Carrascal, E. (2013). Toxoplasmosis of the spinal cord in an immunocompromised patient: case report and review of the literature. Colombia Médica, 44, 232-235.
*Saldarriaga-Cantilloa, A., Bravoa, L. E., Londoño, O., García, L. S., y Collazosa, P. (2012). Epidemiological surveillance of the HIV/AIDS complex through the analysis of trends in the incidence of Kaposi’s sarcoma in Cali, Colombia. Colombia Médica, 43, 273-280.
*Sayan, M., Sargyn, F., Inan, D., Yyldyz-Sevgi, D., Kocagul, C.A., Cagatay, A., … Willke, A. (2014). Transmitted drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey. Journal of the International AIDS Society, 17(Suppl 3). doi:10.7448/IAS.17.4.19750
Stepchenkova, T., Martynenko, O., y Yurchenko, O. (2014). Analysis of causes of death among HIV-infected patients of Kiev Regional AIDS Center during 2013. Journal of the International AIDS Society, 17(Suppl 3), 19617. doi:10.7448/IAS.17.4.19617
*Sukthana, Y., Mahittikorn, A., Wickert, H., y Tansuphaswasdikul, S. (2012). A promising diagnostic tool for toxoplasmic encephalitis: tachyzoite/bradyzoitenstage-specific RT-PCR. Int J Infect Diseases, 16, e279–e284. doi:10.1016/j.ijid.2011.12.009
*Tanon, A., Jaquet, A., Ekouevi, D. K., Akakpo, J., Adoubi, I., y Diomande, I. (2012). The Spectrum of Cancers in West Africa: Associations with Human Immunodeficiency Virus. PLoS ONE, 7. doi:10.1371/journal.pone.0048108
*Thariat, J., Kirova, Y., Sio, T., Choussy, O., Vees, H., Schick, U., … Miller, R. C. (2012). Mucosal Kaposi sarcoma, a Rare Cancer Network study. Rare Tumors, 4, e49. doi:10.4081/rt.2012.e49
*Unemori, P., Leslie, K. S., Hunt, P. W., Sinclair, E., Epling, L., Mitsuyasu, R., … Maurer, T. A. (2013). Immunosenescence is associated with presence of Kaposi's sarcoma in treated HIV infection. AIDS, 27, 1735–42. doi:10.1097/QAD.0b013e3283601144
*von Braun, A., Braun, D. L., Kamarachev, J., Günthard, H. F. (2014). New Onset of Kaposi Sarcoma in a Human Immunodeficiency Virus-1-Infected Homosexual Man, Despite Early Treatment, Sustained Viral Suppression, and Immune Restoration. Open Forum Infectious Diseases, 1. doi:10.1093/ofid/ofu005
*Xavier, A. G., González-Cademartori, B., Azevedo-Da Cunha-Filho, N., y Da Rosa-Farias, N. A. (2013). Evaluation of seroepidemiological toxoplasmosis in hiv / aids patients in the south of Brazil. Rev. Inst. Med. Trop. Sao Paulo, 55, 25-30.
*Xiao, J., Gao, G., Li, Y., Zhang, W., Tian, Y., Huang, Y., Zhao, H. (2013). Spectrums of Opportunistic Infections and Malignancies in HIV-Infected Patients in Tertiary Care Hospital, China. PLoS ONE, 8. doi:10.1371/journal.pone.0075915
Yohanes, T., Debalke, S., y Zemene, E. (2014). Latent Toxoplasma gondii Infection and Associated Risk Factors among HIV-Infected Individuals at Arba Minch Hospital, South Ethiopia. AIDS Research and Treatment, 2014. doi:10.1155/2014/652941
*Zoufaly, A., Jochum, J., Hammer, R., Nassimi, N., Raymond, Y., y Burchard, G. D. (2014). Determinants of HIV-1 drug resistance in treatment-naıve patients and its clinical implications in a treatment program in Cameroon. Journal of the International AIDS Society, 17(Suppl 3). doi:10.7448/IAS.17.4.19615